The content on this site is intended for healthcare professionals only
Dr Oleg Gluz speaks to ecancer about the multicenter ADAPTcycle trial. This study investigated the impact of age and ovarian function suppression (OFS) on endocrine response to short-preoperative endocrine therapy (ET).
ADAPTcycle confirms ADAPT ET-response rates in patients receiving tamoxifen or aromatase inhibitors; adding OFS improves ET-response, irrespective of recurrence score. Endocrine therapy response measurement adds value to therapy decisions, particularly in 50-year-old or above patients.
The study found that optimal preoperative ET, especially in premenopausal patients, might even enable sparing chemotherapy in additional patients.
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
ASCO 2023: Breast cancer research highlights
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA repair-deficient tumours
The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer
